TRANSLATION 2025 is a two-day conference bringing together leading researchers to discuss the latest discoveries and innovations in dementia research.
SCOPE OF THE CONFERENCE
Recent new drugs impacting dementia's progression, new drives in data research, biomarker studies, international collaborations, a growing infrastructure, effective trials delivery capacity are all important elements for translational research. So too, is experimental research as we seek to find new disease-modifying treatments for dementia.
250 delegates, from academia, industry and the third sector will be attending at The Congress Centre in London who are hosting us for the second time.
In addition to the main session during our busy 2-day conference, we are holding an Early Career Researcher morning which has proved extremely popular for those in the earlier stages of research in this field.
The conference will be at The Congress Centre, Great Russell Street, London on 13-14th March 2025.
BOOK NOW
DON'T DELAY! Booking closes on February 14th
ECRs register for only £60.
©
DPUK
Introducing our speakers
SPEAKERS
 |
KEYNOTE SPEAKER: Embracing Complexity Professor John Gallacher University of Oxford; Director, Dementias Platform UK John is Professor of Cognitive Health at Oxford University Department of Psychiatry, and Director of Dementias Platform UK. He is also Director of the BrainWaves Cohort Study, Executive Chair of the MND Translational Accelerator. Since 2014, he has worked as Director of DPUK; bringing together expertise from universities, charities, and pharmaceutical and technology companies into a high-trust, pre-competitive, collaborative environment. The mission of DPUK is to reduce barriers to translating discoveries into treatments by enabling rapid data access through its Data Portal, precision trials through the Trials Delivery Framework, and an industry-led experimental medicine portfolio through the EM Incubator. Since inception, DPUK has leveraged >£100m for dementia translation. He has over 40 years’ experience in psychology and epidemiology, focussing on cohort studies. His, research interests include neurodegeneration, ageing, cognition, and lifestyle. He was PI for the Caerphilly Prospective study (CaPS) and served for over 15 years on the Steering Committee for UK Biobank.
|
| THE USE OF BIOMARKERS IN EXPERIMENTAL MEDICINE | |
|
|
KEYNOTE Professor Donna Wilcock Indiana University School of Medicine Donna Wilcock, PhD is a professor of neurology and Director of the Center for Neurodegenerative Disorders at Indiana University School of Medicine. She is also the Barbara and Larry Sharpf Professor in Alzheimer's Disease Research, a member of Stark Neurosciences Research Institute, and a member of the Indiana Alzheimer's Disease Research Center (IADRC). Dr. Wilcock's research focuses on the intersection of Alzheimer's disease and vascular cognitive impairment and dementia. Using mouse models and patient samples, Dr. Wilcock is exploring the role of neuroinflammation and dysregulated angiogenesis in VCID. In addition, she has several active projects exploring the underlying mechanisms of beta-amyloid immunotherapy-related ARIA. Her research is funded by the NINDS and NIA. |
 |
Dr Pawel Markiewicz University College London Pawel Markiewicz, PhD, is a Senior Lecturer in Computer Vision and Medical Imaging within the Division of Computer Science and Informatics at the School of Engineering, LSBU, and holds an honorary position with the Department of Medical Physics and Biomedical Engineering, as well as The Hawkes Institute at UCL. With a background in nuclear physics and computational modelling, Pawel has led the development of NiftyPET (https://niftypet.readthedocs.io/), a standalone open-source software for high-throughput image reconstruction and analysis. NiftyPET has been used extensively in brain imaging for dementia research and clinical trials involving amyloid tracers, offering advanced tools for pattern recognition, uncertainty estimation, image registration, and segmentation. In addition, he developed AmyPET (https://github.com/AMYPAD/AmyPET), an open-source package designed for amyloid imaging aimed at Alzheimer's disease prevention. AmyPET has been utilized in the Dementia’s Platform UK (DPUK) harmonization study, involving eight PET/MR scanners across the UK, and in the analysis of PET datasets across the AMYPAD (https://amypad.eu/) consortium sites in Europe.
|
 |
Dr Francesca Cormack Cambridge Cognition Francesca is Chief Scientist at Cambridge Cognition, leading the company’s scientific strategy and delivery. She has extensive experience in cognitive neuroscience and cognitive test development in a range of clinical populations. Since joining Cambridge Cognition in 2014, Francesca has worked to develop novel cognitive testing methodology to support high-frequency, near patient testing using digital technology, providing researchers and healthcare providers with unique insights into cognitive health. Francesca obtained a PhD in Dementia with Lewy Bodies at Newcastle University, followed by post-doctoral and academic positions at University College London and at the Medical Research Council in Cambridge. She maintains academic collaborations focused on neurological disorders, ageing and dementia.
|
 |
Dr Ivan Koychev Imperial College, London Ivan is a Clinical Reader in Neuropsychiatry at Imperial College London. He is a clinical academic psychiatrist (on the GMC Specialist Register for Old Age and General Adult Psychiatry) with a focus on the development of treatments for neuropsychiatric disorders. His research interest lies in neurodegeneration experimental medicine studies in humans, testing of repurposed compounds, development of stratification and efficacy biomarkers, and creation of infrastructure for large-scale stratified recruitment into neuroscience trials. He leads a trial exploring the effects of a glucagon-like peptide-1 receptor agonist, semaglutide, on neuroinflammation and tau accumulation in people at risk for dementia. He also co-leads the READ OUT programme that evaluates the real-world utility of blood biomarkers for dementia. Within DPUK, Ivan leads the Great Minds register and Clinical Studies Register of research volunteers, as part of the Trials Delivery Framework. |
|
DATA: FROM 'OMICS TO LINKAGE |
|
|
|
KEYNOTE SPEAKER Professor Art Toga University of Southern California Art is Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Biomedical Engineering, and Director of the USC Mark and Mary Stevens Institute of Neuroimaging and Informatics. One of the world’s leading authorities on neuroimaging, informatics, AI applications in neuroscience, mapping brain structure and function, and brain atlasing. Dr. Toga’s research focus is in neurodegenerative disease and specifically works on Alzheimer’s disease. His interdisciplinary work led to the creation of the Laboratory of Neuro Imaging (LONI), which he also directs and is one of the most advanced multidisciplinary neurological research centers in the world serving numerous multisite neuroscience projects globally. Funded by National Institutes of Health (NIH) grants as well as industry partners, LONI houses one of the largest computing facilities and largest brain image repository in the world. He is an author or co-author of more than 950 peer-reviewed papers, 1200 abstracts and 80 book chapters or books, among them, the Brain Mapping Trilogy. He is the founding editor of the journal NeuroImage. Dr. Toga has received numerous awards for his ran Award for Scientific Innovation and Giovanni DiChiro Award for Outstanding Scientific Research and teaching, including the Pioneer in Medicine Award, Smithsoni. He holds the Ghada Irani chair in Neuroscience and has been on the Thomson Reuters' Highly Cited Researchers for many years. |
 |
Professor Michele Hu University of Oxford, Nuffield Department of Clinical Neurosciences Michele Hu is a clinician neuroscientist working in the field of longitudinal cohort studies and biomarkers for manifest and prodromal Parkinson’s disease, with particular focus on REM sleep behaviour disorder (RBD). Her interests include the delivery of tractable, low cost, wearable technology that has a real impact on patient’s daily lives, alongside imaging the human brain from prodromal to established Parkinson’s. She has led the Oxford Discovery cohort (OPDC: https://opdc.medsci.ox.ac.uk/home) since 2010, exemplifying multi-disciplinary translational neuroscience in Oxford at its best. Its goal is to improve understanding of the biology of early Parkinson’s and identify predictors of Parkinson’s onset and progression using patient cohorts, stem cell models and transgenic rodent lines. Longitudinal motor, non-motor, cognitive and psychiatric phenotyping is performed in 1700 individuals and combined with digital, transcriptomic and imaging data to stratify and predict Parkinson’s, improving future trial delivery. Innovative statistical approaches have allowed the team to understand baseline individual differences in Parkinson’s and how this affects progression, while testing combinations of prognostic biomarkers for individual stratification and trial design. She is strongly committed to improving public engagement with research and promoting outreach activities, helping to shape and focus future research. |
 |
Dr Carole Dufouil University of Bordeaux Carole Dufouil is an epidemiologist, Research Director at Inserm (the French National Institute of Health and Medical Research) and leads the PHARes team (Population Health trAnslational Research) at the Bordeaux Population Health Research Center, based in Bordeaux, France. Her research focuses on understanding the progression of dementia and Alzheimer’s disease (AD), with particular attention to factors such as vascular risks, cognitive stimulation throughout life, and fluid and neuroimaging biomarkers associated with AD and accelerated brain aging. Dr. Dufouil has played a key role in major French cohort studies, including the 3C-Dijon study and the Memento study, which aim to unravel the complexities of brain health and disease progression. In addition to her scientific research, she founded the MELODEM project, an international initiative that seeks to standardize methodological approaches for longitudinal studies on dementia. Currently, Dr. Dufouil also serves as Program Officer at the French Ministry of Research, where she oversees health data policy programs. |
 |
Dr Tim Rittman University of Cambridge Timothy Rittman is an Alzheimer’s Research UK Senior Fellow, Senior Clinical Research Associate at the University of Cambridge and Honorary Consultant Neurologist at Addenbrookes hospital. His research centres around neurodegenerative tauopathies, combining neuroimaging, cognitive assessments and neuropathology to understand how these diseases affect the whole brain. He also has an interest in translating methods from artificial intelligence and big data for use in memory clinics, and leads the Quantitative MRI in NHS Memory Clinics (QMIN-MC) study collecting real world data for validation of AI models. Tim co-leads the DEMON dementia network’s Imaging Working group and is an adviser to the World Young Leaders in Dementia. He is a consultant in the Addenbrookes Memory Clinic, and leads a clinic for people with Progressive Supranclear Palsy and Corticobasal Degeneration, in addition to co-leading a dementia genetics clinic.
|
| TRIALS DELIVERY. TRIALS FOR ALL | |
 |
KEYNOTE SPEAKER: Trials Delivery. Trials for all. Professor Cath Mummery Cath is a Professor of Neurology and consultant neurologist at the National Hospital for Neurology and Neurosurgery. She is chair of the NIHR Dementia Translational Research Collaboration, and Director of the NIHR UK Dementia Trials Network, building a national unified trials network for early phase clinical trials and working with the Mission to accelerate and enhance dementia translational research in novel treatments. She is Head of Clinical Trials at the Dementia Research Centre at University College London. She has been chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer’s disease (AD), and genetic forms of AD and frontotemporal dementia. As clinical lead for the UCL Neurogenetic Therapies Programme, she leads a programme of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia. Her driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer’s, but that we can deliver them promptly, safely and equitably. |
 |
Professor Paresh Malhotra Imperial College London Paresh Malhotra is National Specialty lead for Dementia and Neurodegeneration in the NIHR Research Delivery Network, Head of the Division of Neurology at Imperial College London, and Honorary Consultant Neurologist at Imperial College Healthcare NHS Trust. He carries out Cognitive Neurology clinics at Charing Cross Hospital and his research mainly focusses on Alzheimer’s Disease and Vascular Dementia. He led the recently completed NIHR-funded NorAD repurposing trial and is co-leading a planned multi-arm platform trial in symptomatic Alzheimer’s Disease (AD-SMART). He sits on the NIHR Dementia Translational Research Collaboration, is Vice Chair of the Alzheimer’s Society Research Strategy Council and an Associate Member of the UK Dementia Research Institute. |
 |
Professor Charles Marshall Queen Mary University of London Charles Marshall is an academic neurologist at the Centre for Preventive Neurology at QMUL. He leads a programme of dementia research with focusses on prevention, health inequalities and early diagnosis of dementia. He works clinically in both a tertiary neurology cognitive disorders clinic and a community memory clinic. He is the Clinical Director for Dementia for London. |
 |
Dr Ruth Croney Clinical Operations Portfolio Lead, Roche Products Ltd Ruth Croney has over 25 years of clinical research experience. She has held various roles in clinical operations trial management and project leadership positions during her career. Her therapeutic area experience spans Neuroscience (Neurodegeneration and Psychiatry), Oncology and Immunology for global Phase I to III trials. Ruth is currently the Clinical Operational Portfolio Leader for Roche across the AD franchise . She has worked at Roche since 2005 and during her tenure, she has been awarded an Inventor medal in Feb 24 ; Leadership medal in Dec 2023 and previously awarded the Roche Pharma development breakthrough award in recognition for “Fostering Learning and Creativity “ for her partnering with patients. She has an MSc in Parasitology from the London School of Tropical Medicine and she originally started her career working in Kenya as a research scientist in a field based disease prevention programme against Schistosomiasis. Ruth is based in Hertfordshire. |
Thursday 13th March – Day 1
Early Career Research (ECR) pre-conference workshop
|
Welcome |
09.00 |
ECR Workshop open – poster set-up |
|
ECR Workshop |
10.00 |
ECR Workshop introduction & DPUK overview Prof Sarah Bauermeister (Oxford University) |
|
10.10 |
Opportunities available at ARUK Jacqui Hanley (Alzheimer’s Research UK) |
|
|
10.30 |
Opportunities for ECRs, including the importance of PPIEs Cherie Nyota (Alzheimer’s Society) |
|
|
10.50 |
Data Portal overview Emma Squires (Swansea University) |
|
|
11.00 |
Training and mentoring opportunities Prof Sarah Bauermeister (Oxford University) |
|
|
11.10 |
ECR presentation: Novel biomarker exploration within neuropathologies exhibiting netrin-1 pathway linked cognitive impairment Chelsea Povall (Alchemab) |
|
|
|
ECR presentation: Ultra-processed food intake and cognitive outcomes: a systematic review. Meggie Smith (University of Oxford) |
|
|
11.30 |
Career presentations:
|
|
|
11.45 |
Lessons learned from Lewy Prof John O'Brien (University of Cambridge) |
|
|
12.15 |
Q&A: Ask the panel |
|
|
|
12.30 |
Close |
Main conference Programme
|
|
11.30 |
Conference open – poster time |
|
|
12.00 |
Lunch - Refreshments, poster and stand time |
|
Introductory address |
1.00 |
Welcome |
|
Plenary |
|
Plenary presentation: Preparing for Next-Gen Therapies Professor John Gallacher, Director, Dementias Platform UK, University of Oxford |
|
Use of Biomarkers in Experimental Medicine
|
|
Theme overview by session chair (Prof James Rowe, Cambridge University) |
|
|
Keynote State of the Science of Plasma Biomarkers of Alzheimer’s Disease and Related Dementias |
|
|
|
PET/MRI Imaging in Dementia: Revolutionizing Clinical Trial Reliability and Efficiency Dr Pawel Markiewicz (University College London) |
|
|
3.10 |
Break – Refreshments and poster time |
|
|
|
The role of digital cognitive assessments in dementia drug development: responding to emerging challenges. Dr Francesca Cormack (Cambridge Cognition) |
|
|
|
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders Dr Ivan Koychev (Imperial College, London) |
|
|
|
ECR flash talk: Drug repurposing for dementia in UK Biobank and SAIL cohorts Dr Jodi Watt (University of Glasgow) |
|
|
|
ECR flash talk: Can sodium be used as a biomarker for vascular dementia? Evidence for widespread disturbed brain sodium homeostasis Dr Sasha Philbert (University of Manchester) |
|
|
|
General discussion |
|
|
|
5.30 |
Drinks reception |
|
Close |
6.30 |
Guests depart |
Friday 14th March - Day 2
|
|
8.30 |
Conference open – Poster time |
|
|
9.00 |
Introduction A lived experience by Tim Little |
|
Data: From ‘omics to linkage
|
|
Theme overview by session chair (Prof Simon Thompson, Swansea University) |
|
|
Keynote A Global Approach to Informatics in ADRD |
|
|
|
Digital Technology in Parkinson's Disease Prof Michele Hu (University of Oxford) |
|
|
|
Role of AD Biomarkers in Dementia Research: an Epidemiological Perspective Dr Carole Dufouil (University of Bordeaux) |
|
|
11.00 |
Break – Refreshments, poster and stand time |
|
|
|
AI in Dementia Neuroimaging for Memory Clinics Dr Tim Rittman (University of Cambridge) |
|
|
|
ECR flash talk: AI-guided detection of Alzheimer’s disease based on blood markers and cognition outperforms biomarker-based diagnosis. Dr Chao Dong (University of Cambridge) |
|
|
|
ECR flash talk: Dynamics of cognitive variability with age and its genetic underpinning in NIHR BioResource Genes and Cognition cohort participants Dr Shafiqur Rahman (University of Cambridge) |
|
|
|
General discussion |
|
|
|
12.40 |
Lunch - Refreshments, poster and stand time |
|
|
1.35 |
Presentation of ECR Poster Prizes |
|
Trials delivery: Trials for all
|
|
Theme overview by session chair (Prof Vanessa Raymont, Oxford University) |
|
|
Keynote The Next Generation of CLinical Trials for Alzheimer's Disease |
|
|
|
Developing a Platform Trial in Symptomatic Alzheimer's Disease Prof Paresh Malhotra (Imperial College London) |
|
|
|
Equitable and Representative Trials Delivery in the UK Prof Charles Marshall (Queen Mary, University of London) |
|
|
3.30 |
Break – Refreshments, poster time |
|
|
|
Advancing Alzheimer's Disease Clinical Trials in the UK Dr Ruth Croney (Roche) Roche Products Limited has provided financial support for this meeting but has not been involved in the agenda other than this organised presentation |
|
|
|
ECR flash talk: Gotcha! A trial of an app-based therapy for proper name anomia in people with dementia Dr Aygun Badalove (University College London) |
|
|
|
ECR flash talk: Cross-sectional and longitudinal spectral differences in MEG brain networks differentiate Amyloid-positive Alzheimer’s patients Dr Mats van Es, University of Oxford |
|
|
|
General discussion |
|
|
Closing address |
5.10 |
The future landscape Prof John Gallacher (Oxford University), Director of Dementias Platform UK |
|
|
5.20 |
Close |
Early Career Researchers are important to Translation 2025. ECRs get a heavily discounted rate of only £60 which includes a dedicated Early Career Researcher session at the start of the conference, AND an opportunity to present a Poster or Flash Talk.
CRITERIA TO QUALIFY AS AN ECR AT TRANSLATION CONFERENCES
DPUK’s formal definition of an ECR is an individual who:
- is within ten years of the award of their PhD or equivalent professional training,
- is within six years of their first academic appointment.
These durations exclude any period of career break, e.g. for family care or health reasons. The ‘first academic appointment’ is defined as the first paid contract of employment, either full-time or part-time, which lists research and/or teaching as the primary functions.
Translation 2024 is generously supported by our sponsors. You will be able to meet them at the conference. DPUK is grateful to all of them. We wish to be clear that our sponsors have provided support to Dementias Platform UK to cover the cost of running the conference, and that no sponsor has had any influence over the meeting's agenda or arrangements.
OUR SPONSORS FOR TRANSLATION 2025
 |
Alamar Biosciences is unlocking the future of neurological diagnostics with high-sensitivity and multiplex protein detection in biofluid samples. The NULISAseq™ CNS Disease Panel 120 provides multiplex analysis of biologically informed content with the highest-sensitivity and broadest dynamic range. Analysis of 120+ proteins supports protein biomarker discovery and validation studies and includes biomarkers such as GFAP, UCH-L1 and alpha-synuclein. Complementing this, the NULISAseq™ Inflammation Panel contains ~250 important markers enabling comprehensive analysis of immune and inflammatory diseases. The NULISA immunoassays run on the innovative ARGO™ HT System, delivering a fully automated workflow and comprehensive multiplex data analysis in <16 hours. |
 |
The Alzheimer’s Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share unpublished data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures in Alzheimer’s disease and related dementias. Learn more about the Alzheimer’s Disease Data Initiative at www.alzheimersdata.org. |
 |
Alzheimer’s Research UK is the UK’s leading dementia research charity. We are working to revolutionise the way we treat, diagnose and prevent dementia. And then, we will find a way to cure it. To do this, we’re funding the most forward-thinking scientists. In 2024, we invested £25.7m across 26 institutions through our grant schemes. These grants span PhD scholarships to pilot projects to senior fellowships. They cover a range of disease types, including Alzheimer’s and Parkinson’s disease, Frontotemporal and Vascular dementia, and dementia with Lewy Bodies. To find out more, please visit our website. |
 |
To tackle the UK’s biggest killer, we need a Society of people who understand all aspects of dementia and the realities of a disease faced by 900,000 people in the UK. We’re pioneering the way for those experiencing dementia right now, and for all those yet to develop the disease in the future. As well as being a vital source of support to help people navigate the most frightening time of their lives, we’re a powerful force for change by funding groundbreaking research and campaigning to make dementia the priority it should be. |
 |
At Eisai, everything we do is dedicated to giving our first thought to patients, their families and caregivers through our human health care (hhc) philosophy. Our passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in therapeutic areas where there is a high unmet medical need, such as neurology. We take a holistic approach to support and care, focusing beyond symptom control to research and discover life-changing medicines for patients with chronic neurological disorders. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational workforce working across a global network of R&D facilities, manufacturing sites and committed marketing subsidiaries. We strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. |
 |
|
 |
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit www.novonordisk.co.uk |
 |
RETURN TO TRANSLATION 2024 MAIN PAGE
LOCATION
The Congress Conference Centre is at 28 Great Russell Street, London WC1B 3LS
Tel: 020 7467 1318
TRAVEL
Underground
The nearest tube to the Congress Centre is Tottenham Court Road using these lines:
Walking from main rail terminals
- Euston (18 mins)
- Kings Cross/St Pancras International (30 mins)
- Charing Cross (19 minutes)
- Waterloo Station (32 mins)
Find it easily with what3words - ///mimic.easy.winter (https://what3words.com/mimic.easy.winter)
Click on this map for a detailed view
RECOMMENDED HOTELS
The Congress Conference Centre is ideally located in Bloomsbury. The area has a number of hotels and you will probably find accommodation within walking distance of our venue. The hotels below are popular with Congress Centre events, due to their quality and proximity. However, there are 100s nearby hotels to choose from.
Travelodge London Covent Garden
15-minute walk
10 Drury Ln, High Holborn, London WC2B 5RE
St Giles London - A St Giles Hotel
5-minute walk
12 Bedford Ave, London WC1B 3GH
Zedwell Underground Tottenham Court Road
7-minute walk
112a Great Russell St, London WC1B 3NQ
hub by Premier Inn London Goodge Street hotel
11-minute walk
Brook House, Torrington Pl, London WC1E 7HN
12-minute walk
75 Kingsway, London WC2B 6SR
Here are some Frequently Asked Questions about Translation 2024.
If you cannot find the information you need here, please email us: at dpuk@psych.ox.ac.uk
When is the DPUK Translation 2025 conference?
Thursday 13th and Friday 14th March 2025.
What are the start and finish times of the conference?
The pre-conference ECR Workshop starts at 10am and finish at 12 noon GMT on Thursday 13th March 2025.
The main conference will begin at 1.15pm on Thursday 13 March. We will be able to register from 11.30am. The main conference will close at 5.pm that day, followed by a drinks reception until 6pm.
The main conference continues on Friday 14th March starting at at 9am, and finishing at 5.20pm GMT
Where is the conference?
Translation 2025 is taking place at CONGRESS CONFERENCE CENTRE, 28 Great Russell Street, London WC1B 3LS.
I am an Early Career Researcher (ECR) - do I have to pay full price?
The special ECR price to attend is £60 GBP. ECRs are very welcome to attend the pre-conference ECR workshop and also submit an abstract. If this is accepted you will be invited to produce either a Poster or a Flash Talk. Prizes will be given to the best posters and Lightning Talk presentations as agreed by the judges.
How do I get to the venue?
The Congress Conference Centre is at 28 Great Russell Street, London WC1B 3LS
Tel: 020 7467 1318
Nearest Underground station: Tottenham Court Road
Find it easily with what3words - ///mimic.easy.winter (https://what3words.com/mimic.easy.winter)
Who are the main speakers at the event?
We are delighted to announce that our keynote speakers are Professor Sir John Hardy, Professor Catherine Mummery, Professor Art Toga, and Professor Henrik Zetterberg. Further information will be updated soon.
Is there an Early Career Researcher (ECR) event?
Yes, we have an Early Career Researcher event on the morning of Thursday 13th March.
Is the conference available online/virtually?
Due to the highly collaborative and 'workshop-like' nature of the event, Translation 2025 will only be in-person. We will be recording the event and selected talks will be available to watch online after the conference.
How do I pay for my place at the conference?
At the end of the registration process, you will find details of how to pay.
Is there a deadline for payment?
Registration closes on 13th February 2025.
Will I be able to get a copy of the presentations?
Each speaker will be asked to make their presentations available to share after the event, but as this is at the discretion of the speaker, we cannot guarantee all will be available.
I can no longer attend - can I appoint a colleague to attend in my place?
This will be at the discretion of the event organisation team. If your circumstances change, please let us know as soon as possible at dpuk@psych.ox.ac.uk.
Can I amend my booking after completion?
Not directly - if you need to update your details, please contact dpuk@psych.ox.ac.uk to discuss further.
I am a speaker at one of the sessions, can I bring someone else along free of charge with me?
Unfortunately, only one place per speaker is complimentary.
I am a speaker at one of the sessions, do I need to register?
Yes. Although speakers get complimentary places, you need to register for insurance, security and venue capacity reasons.
What is your cancellation and refund policy?
The cancellation and refund policy for online ticket purchases (both Standard and ECR) will be in line with the University of Oxford's Online Sales Systems Terms and Conditions. To summarise the relevant paragraphs in Section 7, we aim to refund the following proportions of the balance of the conference fee:
- Cancellation more than 2 weeks before the start date: 100%
- Cancellation 1-2 weeks before the start date: 50%.
- Cancellation less than 1 week before the start date: 0%
Is there WiFi available at the venue?
Yes, you will be given the WiFi network access details when you arrive at The Congress Centre.
For any other questions regarding Translation 2025, please get in touch with us at dpuk@psych.ox.ac.uk